BioSpace News Archive

Second Sight Medical Products, Inc., a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announced results of its annual meeting held May 28, 2021.

SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced that management will participate in a Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8th at 3:00PM ET.

Life-long support with free-of-charge and proactive variant reclassification demonstrates unique commitment to improving the lives of patients with rare diseases

Quotient Limited, a commercial-stage diagnostics company, headquartered in Eysins, Switzerland, reported its fourth quarter fiscal 2021 key achievements and summarized recent business developments.

ZYESAMI™ is the First Investigational Medicine to Show Efficacy in a Randomized, Double-Blind, Multicenter Trial, Achieving More Instances of Recovery in Critically Ill COVID-19 Patients with Respiratory Failure, Compared to Placebo

Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, announced the appointment of Inderpal Singh as General Counsel

A new study using a cutting-edge technology to potentially predict certain birth defects wins the 2021 award for best paper published in the journal Birth Defects Research.

Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, announced that Michael F. MacLean, chief financial officer of Avidity Biosciences, has joined the company’s board of directors.

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced that restoration of retinal tissue was observed in two additional patients enrolled in the Company’s Phase 1/2a study of its lead product candidate, OpRegen.

This combination vaccine may simplify execution and reduce shots needed to complete CDC’s recommended child and adolescent immunization schedule